We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
26/1/2021 15:30 | About time | markstevenkirby80 | |
26/1/2021 15:28 | Americans seem to like it fran, outlining our pipeline that could produce $$$$$$$$Big bucks soon........... | mark0419 | |
26/1/2021 15:23 | Some confident people on twitter today that we'll see that big RNS. | mark0419 | |
26/1/2021 15:22 | Good old US of A pulling us up before possibly the big game changer RNS. Immenant. | mark0419 | |
26/1/2021 15:21 | Up 12% stateside and rising! | jpuff | |
26/1/2021 15:14 | Sure is but the UK is lagging, could it be to align the listings as there is still continued disparity between listings... | rebelwithacause1 | |
26/1/2021 15:12 | I'm not sure Fan because it's been disclosed in the past, maybe its a concise version for the 'Ignorant' masses. However, funding is confirmed until the end of 2022, not an enormous amount of time, especially within the 'Trials and Tribulations' of BioPharma...And there doesn't seem to be any contigency which is worrying if it doesn't go to plan when other prominent trials may not even come to fruition with a lack of funding from their 'Significant Pipeline'...but there's always the potential of an RI... | rebelwithacause1 | |
26/1/2021 15:07 | U.S likes it , up9% at the mo | heliman2 | |
26/1/2021 14:57 | What was the relevance of today’s RNS? | fandagle | |
26/1/2021 14:28 | See my dear friend Walkmi, a 'Common' investor like yourself filters when investing is becoming rather sentimental, if you get my drift...just don't lose your 'Shirt' hey! ...AbbNat, such history we have but if its any consolation, I have no plans to leave my humble abode here - hehe! ...And there goes the 'Fool with his ohh so little Tool' Mark0419, posted from a confident poster on the LSE, I do wonder whether thats you - oops! ...By the way Yid, so do you see by your comment as to why the masses will not realise the 'Potential' here...And I wasn't aware any traction whatsoever with licensing had been achieved especially when 'Proof of Concept' hasn't even been validated yet through the obligatory 'Peer Reviews' - such expertise you have within Biopharma but stretches the truth somewhat! | rebelwithacause1 | |
26/1/2021 14:10 | Well the 'Champ' is back! Had a few other things to contend with this mornining so my sincere apologies for the delay - hehe! A few facts though... Firstly, Dr Neil Graham did not leave Regeneron for Tiziana - I think you'll find he was at the transition of retiring not transferring from one company to the other folks! Secondly but most importantly investors are selling not due to impatience but not realising their investments on the 'Efficacy of trials' which have considerable risk, especially where human lives are involved...And if it was so assured by KSs 'Fireside chat, why is it languishing... Lastly but just as important - loving the comedy my dear friend Fan! | rebelwithacause1 | |
26/1/2021 13:02 | At this rate we will be returning back to Aim as we slide down the ftse :) | twodegrees | |
26/1/2021 11:52 | The development path smaller Biotechs usually follow is to get their assets part or fully through Phase 2, by which point big pharma take much more of an interest. It is at that point that licensing deals tend to take place in the form of upfront payments, milestone payments covering the final development (phase 3, NDA etc) and licensing deals. The alternative which Celgene, Tesaro and many others have followed is they get acquired in their entirety. | yidarmytom | |
26/1/2021 11:00 | Millionaires will be buying at 50p. | small crow | |
26/1/2021 10:48 | We are cashed up, transformational data due in next few days, great bod with a fantastic new addition to the team recently. Great pipeline. Sounds pretty compelling reason to invest for me. The reason for the sell off is the same reason why 70% of peopleLose money on the markets.. no patience to hold for more then 5 mins. Panic at first sign of red. If it was easy we would all be millionaires. | mark0419 | |
26/1/2021 09:46 | Not looking good in Brazil for Covid-19 patients running out of oxygen cylinders now..........https:/ | mark0419 | |
26/1/2021 09:30 | Copied from a confident poster off LSE................. | mark0419 | |
26/1/2021 09:26 | https://ir.tizianali | mark0419 | |
26/1/2021 09:14 | Shame how we never see you add to the story here? | mark0419 | |
26/1/2021 09:13 | With the last dosed person of the Covid-19 treatment being last week of December. Will we get the results this week. In the fireside chat he mentioned a few weeks surely it must be imminent. Next extended trial needs to be started ASAP. | mark0419 | |
26/1/2021 07:55 | Walki sorry you feel that way, would like nothing better than to log on and Reb has disappeared. I will ignore him from now on, as yes, it only perpetuates his drivel. | impala391 | |
26/1/2021 07:37 | if we get this then we will be rapidly moving to a large expansion of the trial Primary endpoints: Safety and tolerability Nasal tolerance Secondary endpoints: Reduction in use of ventilators, Disease symptoms, PRO TNSS questionnaire, Smell sensation and appetite Biomarkers to assess clinical effects, Immunology (Tregs), Pharmacokinetics | yidarmytom | |
26/1/2021 07:19 | Trial completed: Topline data expected in late January 2021 | jostrummer | |
26/1/2021 07:06 | I agree ABBYNAT, the more people who filter Rebel, ivan, munch etc the better, then we can get this board back to what it should be, discussing the investment case (good and bad) in a sensible polite manner, albeit with banter if warranted! | yidarmytom |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions